All In Biotech

Drug Trial Radar · NCT06834074

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Expanded Access Treatment of Neladalkib (NVL-655) in Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Nuvalent Inc.Industry
Sponsor type
Industry
First posted
Feb 19, 2025

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The Expanded Access Program will provide an alternate mechanism for patients, who lack satisfactory therapeutic alternatives and cannot participate in a neladalkib clinical trial, to access investigational neladalkib.

Conditions

  • Non Small Cell Lung Cancer
  • ALK-positive Non-small Cell Lung Cancer (NSCLC)

Interventions

  • NVL-655Drug

    Drug: NVL-655

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

50 sites in 12 countries. Site status is shown where the registry gives one.

  • University Of California Irvine Medical Center

    Orange, California · Available

  • University of Colorado Anschutz School of Medicine

    Aurora, Colorado · Available

  • University of Chicago Medical Center

    Chicago, Illinois · Available

  • Massachusetts General Hospital

    Boston, Massachusetts · Available

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Available

  • Henry Ford Cancer Institute

    Detroit, Michigan · Available

  • Washington University in St. Louis

    St Louis, Missouri · Available

  • NYU Langone Health

    New York, New York · Available

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Available

  • Duke University

    Durham, North Carolina · Available

  • The Ohio State University

    Columbus, Ohio · Available

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Available

  • University of Washington / Fred Hutchinson Cancer Center

    Seattle, Washington · Available

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Available

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Available

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Available

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Available

  • BC Cancer - Vancouver

    Vancouver, British Columbia, Canada · Available

  • The Ottawa Hospital

    Ottawa, Ontario, Canada · Available

  • Princess Margaret Hospital

    Toronto, Ontario, Canada · Available

  • Centre Leon Berard

    Lyon, Auvergne-Rhône-Alpes, France · Available

  • Institut Gustave Roussy

    Villejuif, Île-de-France Region, France · Available

  • GCS IUCT Oncopole

    Toulouse, Occitanie, France · Available

  • CHU de Nantes

    Nantes, Pays de la Loire Region, France · Available

  • Azienda Ospedaliero Universitaria delle Marche

    Ancona, Italy · Available

  • Istituto Tumori Giovanni Paolo II

    Bari, Italy · Available

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Available

  • L'Istituto Europeo di Oncologia S.r.l.

    Milan, Italy · Available

  • IRCCS Istituto Oncologico Veneto

    Padova, Italy · Available

  • AUSL della Romagna - Ravenna

    Ravenna, Italy · Available

  • IRCCS Istituto Nazionale Tumori Regina Elena

    Rome, Italy · Available

  • Antoni van Leeuwenhoek Hospital

    Amsterdam, Netherlands · Available

  • University Medical Center Groningen

    Groningen, Netherlands · Available

  • Stichting Het Nederlands Kanker Instituut

    Amsterdam, North Holland, Netherlands · Available

  • National University Hospital Singapore

    Singapore, Singapore · Available

  • National Cancer Centre Singapore

    Singapore, Singapore · Available

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Available

  • Seoul National University Hospital

    Seoul, Jongno-gu, South Korea · Available

  • Gerencia de Gestión Integrada A Coruna

    A Coruña, Spain · Available

  • Uomi Cancer Center-Clinica Tres Torres

    Barcelona, Spain · Available

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.